Current Report Filing (8-k)
December 19 2022 - 05:20PM
Edgar (US Regulatory)
0001175680false00011756802022-12-192022-12-19
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, DC 20549
FORM 8-K
Current
Report
Pursuant to Section
13 or 15(d)
of The Securities Exchange Act
of 1934
Date of Report (Date of earliest event
reported): December 19,
2022
CytoDyn Inc.
(Exact name of registrant as specified
in its charter)
|
|
|
|
|
Delaware
|
000-49908
|
83-1887078
|
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification
No.)
|
1111 Main
Street,
Suite 660
Vancouver, Washington 98660
(Address of principal executive
offices, including zip code)
(360) 980-8524
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which
registered
|
|
None
|
|
None
|
|
None
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item
5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
(b) On December 19, 2022, the
Company and Scott A. Kelly M.D., the Company’s Chief Medical
Officer, agreed that Dr. Kelly will resign from his role at the
Company, effective immediately.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
CYTODYN INC.
|
|
|
|
|
|
Date: December 19, 2022
|
By
|
/s/ Antonio Migliarese
|
|
|
|
Antonio Migliarese
|
|
|
|
Chief Financial Officer
|
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Feb 2023 to Mar 2023
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Mar 2022 to Mar 2023
